N-(4,6-二甲基-2-吡啶基)硫代尿 | 49600-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: N-(4,6-二甲基-2-吡啶基)硫代尿
• 英文名称: 4,6-Dimethyl-2-pyridyl-thioharnstoff
• 英文别名: (4,6-dimethyl-pyridin-2-yl)-thiourea；(4,6-dimethylpyridin-2-yl)thiourea
• CAS: 49600-35-3
• 化学式: C₈H₁₁N₃S
• 分子量: 181.261
• InChiKey: ZXQTZSMIBLLDGW-UHFFFAOYSA-N

物化性质

• 熔点：
  238-243℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(4,6-二甲基-2-吡啶基)硫代尿 在 溴 、 sodium methylate 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors

  摘要：

  A series of structurally novel aminothiazole based small molecule inhibitors of Itk were prepared to elucidate their structure-activity relationships (SARs), selectivity, and cell activity in inhibiting IL-2 secretion in a Jurkat T-cell assay. Compound 3 is identified as a potent and selective Itk inhibitor which inhibits anti-TCR antibody induced IL-2 production in mice in vivo and was previously reported to reduce lung inflammation in a mouse model of ovalbumin induced allergy/asthma. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.060
• 作为产物：
  描述：

  2-氨基-4,6-二甲基吡啶 在 sodium hydroxide 作用下， 以 丙酮 为溶剂， 生成 N-(4,6-二甲基-2-吡啶基)硫代尿
  参考文献：
  名称：

  Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors

  摘要：

  A series of structurally novel aminothiazole based small molecule inhibitors of Itk were prepared to elucidate their structure-activity relationships (SARs), selectivity, and cell activity in inhibiting IL-2 secretion in a Jurkat T-cell assay. Compound 3 is identified as a potent and selective Itk inhibitor which inhibits anti-TCR antibody induced IL-2 production in mice in vivo and was previously reported to reduce lung inflammation in a mouse model of ovalbumin induced allergy/asthma. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.060

文献信息

• Tricyclic Thiazolopyrazole Derivatives as Metabotropic Glutamate Receptor 4 Positive Allosteric Modulators
  作者：Sang-Phyo Hong、Kevin G. Liu、Gil Ma、Michael Sabio、Michelle A. Uberti、Maria D. Bacolod、John Peterson、Zack Z. Zou、Albert J. Robichaud、Darío Doller

  DOI：10.1021/jm200290z

  日期：2011.7.28

  There is an increasing amount of evidence to support that activation of the metabotropic glutamate receptor 4 (mGlu4 receptor), either with an orthosteric agonist or a positive allosteric modulator (PAM), provides impactful interventions in diseases such as Parkinson’s disease, anxiety, and pain. mGlu4 PAMs may have several advantages over mGlu4 agonists for a number of reasons. As part of our efforts

  越来越多的证据支持通过正构激动剂或正变构调节剂（PAM）激活代谢型谷氨酸受体4（mGlu4受体），可以对帕金森氏病，焦虑症和疼痛等疾病提供有效的干预措施。 。出于多种原因，mGlu4 PAM可能比mGlu4激动剂具有多个优势。作为我们为帕金森氏病等中枢神经系统（CNS）疾病寻找治疗药物的努力的一部分，我们一直专注于代谢型谷氨酸受体。在此，我们报告了一系列以三环噻唑并吡唑类为mGlu4 PAM的研究。
• Tyrosine kinase inhibitors
  申请人：Merck & Co., Inc.

  公开号：US20020147203A1

  公开（公告）日：2002-10-10

  The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及抑制、调节和/或调控酪氨酸激酶信号传导的化合物，包含这些化合物的组合物，以及使用它们来治疗依赖酪氨酸激酶的疾病和状况的方法，如在哺乳动物中的血管生成、癌症、肿瘤生长、动脉粥样硬化、老年性黄斑变性、糖尿病性视网膜病变、炎症性疾病等。
• EP1218376A4
  申请人：——

  公开号：EP1218376A4

  公开（公告）日：2002-11-20
• TYROSINE KINASE INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1218376A1

  公开（公告）日：2002-07-03
• US5908842A
  申请人：——

  公开号：US5908842A

  公开（公告）日：1999-06-01